Repurposed decellularized amniotic membrane enhances cancer invasion modeling, suggesting improved ECM fidelity.
Modeling cancer cell invasion requires physiologically relevant systems, yet traditional 2D/3D assays and animal models fail to capture the biochemical and mechanical complexity of the human extracellular matrix (ECM). The human amniotic membrane (AM) is a clinically approved, abundant, and immunologically privileged tissue with a rich ECM composition and favorable mechanical properties. Despite its extensive use in regenerative medicine, its potential as a cancer invasion scaffold remains underexplored. We propose repurposing decellularized AM (dAM) as a human-derived ECM platform to study tumor invasion. dAM retains structural proteins, growth factor reservoirs, and stiffness gradients that influence epithelial-to-mesenchymal transition (EMT) and invasion pathways. Compared with conventional matrices, it offers improved biochemical fidelity and compatibility with patient-derived organoids. Key challenges, including donor variability, decellularization optimization, and reproducibility, are also addressed. dAM provides a non-invasive, scalable, and physiologically relevant tool for cancer invasion assays, drug screening, and patient-specific models. Its integration into oncology research may enhance translational relevance and accelerate personalized medicine.
No takes yet. Share an insight, caveat, or question.
Ahmed M. Abou‐Shanab (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: